Cargando…
Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subj...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488506/ https://www.ncbi.nlm.nih.gov/pubmed/35613742 http://dx.doi.org/10.1183/16000617.0230-2021 |
_version_ | 1784792673503150080 |
---|---|
author | Craig, Sonya Pépin, Jean-Louis Randerath, Winfried Caussé, Christian Verbraecken, Johan Asin, Jerryll Barbé, Ferran Bonsignore, Maria R. |
author_facet | Craig, Sonya Pépin, Jean-Louis Randerath, Winfried Caussé, Christian Verbraecken, Johan Asin, Jerryll Barbé, Ferran Bonsignore, Maria R. |
author_sort | Craig, Sonya |
collection | PubMed |
description | Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subjective EDS can be evaluated using the Epworth Sleepiness Scale, in which the patient reports the probability of dozing in certain situations; however, its reliability has been challenged. Objective tests such as the multiple sleep latency test or the maintenance of wakefulness test are not commonly used in patients with OSA, since they require nocturnal polysomnography, daytime testing and are expensive. Drugs for EDS are available in the United States but were discontinued in Europe some time ago. For European respiratory physicians, treatment of EDS with medication is new and they may lack experience in pharmacological treatment of EDS, while novel wake-promoting drugs have been recently developed and approved for clinical use in OSA patients in the USA and Europe. This review will discuss 1) the potential prognostic significance of EDS in OSA patients at diagnosis, 2) the prevalence and predictors of residual EDS in treated OSA patients, and 3) the evolution of therapy for EDS specifically for Europe. |
format | Online Article Text |
id | pubmed-9488506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94885062022-11-14 Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view Craig, Sonya Pépin, Jean-Louis Randerath, Winfried Caussé, Christian Verbraecken, Johan Asin, Jerryll Barbé, Ferran Bonsignore, Maria R. Eur Respir Rev Reviews Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subjective EDS can be evaluated using the Epworth Sleepiness Scale, in which the patient reports the probability of dozing in certain situations; however, its reliability has been challenged. Objective tests such as the multiple sleep latency test or the maintenance of wakefulness test are not commonly used in patients with OSA, since they require nocturnal polysomnography, daytime testing and are expensive. Drugs for EDS are available in the United States but were discontinued in Europe some time ago. For European respiratory physicians, treatment of EDS with medication is new and they may lack experience in pharmacological treatment of EDS, while novel wake-promoting drugs have been recently developed and approved for clinical use in OSA patients in the USA and Europe. This review will discuss 1) the potential prognostic significance of EDS in OSA patients at diagnosis, 2) the prevalence and predictors of residual EDS in treated OSA patients, and 3) the evolution of therapy for EDS specifically for Europe. European Respiratory Society 2022-05-25 /pmc/articles/PMC9488506/ /pubmed/35613742 http://dx.doi.org/10.1183/16000617.0230-2021 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Reviews Craig, Sonya Pépin, Jean-Louis Randerath, Winfried Caussé, Christian Verbraecken, Johan Asin, Jerryll Barbé, Ferran Bonsignore, Maria R. Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view |
title | Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view |
title_full | Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view |
title_fullStr | Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view |
title_full_unstemmed | Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view |
title_short | Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view |
title_sort | investigation and management of residual sleepiness in cpap-treated patients with obstructive sleep apnoea: the european view |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488506/ https://www.ncbi.nlm.nih.gov/pubmed/35613742 http://dx.doi.org/10.1183/16000617.0230-2021 |
work_keys_str_mv | AT craigsonya investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT pepinjeanlouis investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT randerathwinfried investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT caussechristian investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT verbraeckenjohan investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT asinjerryll investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT barbeferran investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview AT bonsignoremariar investigationandmanagementofresidualsleepinessincpaptreatedpatientswithobstructivesleepapnoeatheeuropeanview |